anti bacteria

Gelest, Inc., has received U.S. Environmental Protection Agency approval to use new manufacturing processes for its BIOSAFE antimicrobials, which will significantly expand its production capacities.

Gelest and its suppliers teamed up to overcome material supply shortages to ensure Gelest can meet the surging demand for BIOSAFE from all of its customers, especially healthcare professionals.

Due to the COVID-19 pandemic, the demand for sanitizers, disinfectants, and antimicrobials has skyrocketed, says Gelest in a press release. Suppliers not only have to find ways to expand production capacities, but must also overcome raw material supply shortages due to the disruption of the global supply chain.

“At Gelest, we continue to find new ways to ensure availability of our BIOSAFE antimicrobials to meet our customers’ needs,” says Shiming Wo, Gelest vice president and general manager - Life Science. “For example, we invested in developing new processes with shorter cycle time, and successfully obtained EPA approval for the implementation of these advancements int he manufacturing of our BIOSAFE products. It allowed us to significantly expand our BIOSAFE capacity without compromising our ability to supply products for other critical market segments.”